Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a disease known from a few months, caused by a recently arisen virus and, consequently, it is little known. The disease has a benign course in most infected subjects (children and young adults), is often symptomatic in adults over the age of 50 and often serious and life threatening in people with comorbidities and the elderly. The few data published on coronavirus disease‐2019 (COVID‐19) in the blood‐oncology field report a serious clinical presentation, a serious course of the disease, and a high mortality rate, as has also been reported for other cancer contexts. The current strategy for treating patients with SARS‐CoV‐2 includes antivirals that are effective against other viral infections and drugs that can moderate the cytokine storm. There is no specific vaccine and consequently all possible precautions must be taken to prevent SARS‐CoV‐2 infection in the areas of oncology, oncohematology, and bone marrow transplantation. In this reviewer's article, we report the information currently available on SARS‐CoV‐2 infection to help young doctors and hematologists to successfully manage patients with COVID‐19.

中文翻译：

---

SARS-CoV-2 感染的影响，特别是血液学环境。

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是几个月前才知道的一种疾病，由最近出现的病毒引起，因此鲜为人知。该病在大多数感染对象（儿童和年轻人）中呈良性病程，在 50 岁以上的成年人中通常有症状，在患有合并症的人和老年人中通常很严重并危及生命。在血液肿瘤学领域发表的关于 2019 年冠状病毒病 (COVID-19) 的少数数据报告了严重的临床表现、严重的病程和高死亡率，其他癌症情况也有报道。目前治疗 SARS-CoV-2 患者的策略包括对其他病毒感染有效的抗病毒药物和可以缓和细胞因子风暴的药物。没有特定的疫苗，因此必须采取所有可能的预防措施来预防肿瘤学、肿瘤血液学和骨髓移植领域的 SARS-CoV-2 感染。在这篇评论者的文章中，我们报告了目前有关 SARS-CoV-2 感染的可用信息，以帮助年轻医生和血液学家成功管理 COVID-19 患者。